Engflag

Farxiga

Quick links to important sections

Farxiga

Selected form

There is no image.

Method of action: Antidiabetic, Drugs Used In Diabets

Treatment option: Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Farxiga

Farxiga is an oral, synthetic, prescription medicine used to help manage metabolic conditions, primarily by influencing how the kidneys handle sugar. Its core function is to reduce the amount of glucose circulating in the bloodstream. The drug's classification, composition, and unique mechanism define it as a modern therapeutic option for metabolic and cardiovascular support.

Quick Facts: Farxiga (Dapagliflozin)

Property Description
Active ingredient Dapagliflozin
Form Oral film-coated tablet
Pharmacological class Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor
Common use Metabolic and cardiovascular support
Origin Synthetic aryl C-glycoside

What Type of Medicine is Farxiga? (Classification and Origin)

Farxiga is classified as a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor, a distinct pharmacological class that acts independently of insulin. The active substance is Dapagliflozin, a synthetic compound approved by regulatory bodies. The classification as an SGLT2 inhibitor is critical, establishing the drug's specialized approach to glycemic control through renal action, differentiating it from older agents that target the pancreas or liver. The World Health Organization (WHO) includes Dapagliflozin on its List of Essential Medicines in the category of oral hypoglycaemic agents.

Composition and Form: What is Dapagliflozin?

Dapagliflozin is the sole active ingredient in Farxiga, and it is prepared as an oral, film-coated tablet for once-daily use. The active ingredient is typically formulated as dapagliflozin propanediol monohydrate to ensure stability, which is a key feature of its patented composition. The medicine is delivered as a single-entity product, although fixed-dose combination products containing Dapagliflozin are also available. Being an oral medication, the route of administration is simple, requiring the patient to swallow the tablet.

General Purpose and Mechanism Principle

The general purpose of Farxiga is to manage blood sugar levels by prompting the removal of excess glucose from the body through urination. This action, known as glucosuria, occurs because Dapagliflozin selectively blocks the SGLT2 protein in the kidney, which normally reabsorbs most glucose back into the blood. This unique principle provides a sustained, insulin-independent reduction in high blood sugar, constituting a key benefit in supporting overall systemic health and contributing to its designation as a disease-modifying therapy.

Regulatory References

  1. WHO EML Entry

What side effects are possible with Farxiga?

Possible Side Effects and Safety Information

The safety profile of Farxiga (dapagliflozin) is documented in regulatory submissions that classify adverse reactions based on their frequency and the physiological systems affected, in line with official government regulatory standards. These classifications strictly reflect data observed in clinical studies and post-marketing surveillance.

Classification of Documented Adverse Reactions

The most frequently reported adverse reactions are often linked to the drug’s mechanism of increasing glucose excretion in the urine.

Frequency Classification Key Adverse Reactions
Very Common Hypoglycemia (only when used with insulin or a sulfonylurea)
Common Genital mycotic infections, Urinary tract infections (UTIs), Volume depletion (e.g., hypotension), Increased urination, Nasopharyngitis
Uncommon Thirst, Constipation, Pain in extremity
Rare/Very Rare Diabetic Ketoacidosis (DKA), Fournier's Gangrene (Necrotizing Fasciitis of the Perineum)

Serious and Population-Specific Safety Notes

The regulatory safety text explicitly highlights the risk of Diabetic Ketoacidosis (DKA), including cases where blood sugar levels are not severely high. The very rare, but serious, infection known as Fournier's Gangrene is also documented. Safety considerations exist for specific patient groups: Older adults and individuals with renal impairment may have an increased incidence of reactions related to volume depletion. The medicine is not recommended for use during the second and third trimesters of pregnancy or while breastfeeding. The overall safety documentation focuses on the known risk factors and official frequency-based classifications.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidance regarding Farxiga (dapagliflozin) overdose emphasizes the need for immediate professional medical intervention. While experience with very high doses often reports minimal or no symptoms, the official prescribing information states that a severe overdose can lead to profound physiological effects.

The most critical concerns documented in regulatory sources are those related to fluid balance. Overdose may cause excessive urination (profound diuresis), resulting in severe volume depletion, hypotension (low blood pressure), and electrolyte imbalance. Clinical signs such as dizziness or signs of dehydration may also manifest. In severe cases, complications like acute kidney injury may require hospitalization. For patients taking the drug alongside insulin or sulfonylureas, the risk of hypoglycemia (low blood sugar) is also officially documented.

In the event of a suspected overdose, it is mandated that patients or caregivers seek immediate medical attention and contact emergency services. There is no specific antidote available. Management is strictly symptomatic and supportive treatment, focusing on correcting dehydration and electrolyte issues. Hospital monitoring may be required to observe volume status and blood pressure, especially for high-risk individuals, including the elderly and those with impaired renal function.

Therapeutic Uses of Farxiga

What Farxiga Treats: Main Uses and Benefits

Farxiga (dapagliflozin) is commonly used across therapeutic domains, including for conditions characterized by periods of heightened symptoms such as Type 2 Diabetes, Chronic Heart Failure, and Chronic Kidney Disease. Its use is relevant in contexts marked by increased discomfort or tension.

The medication may be part of symptomatic management for symptoms that interfere with daily functioning. It is relevant for easing the overall symptom load during episodes where symptoms become momentarily overwhelming.

It is commonly used when short-term symptomatic assistance is needed for symptoms associated with acute or episodic changes. The medication may assist with symptom clusters that may become intense or disruptive, offering supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Relevant for Easing Symptoms related to systemic imbalance

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Farxiga (Dapagliflozin)?

Official regulatory information defines specific populations eligible for Farxiga and those who must not use it.

Contraindications and Restrictions

Farxiga is contraindicated in patients with a history of serious hypersensitivity reactions, such as anaphylaxis or angioedema, to dapagliflozin or any of its components. The medicine is also strictly contraindicated for blood sugar control in patients with severe renal impairment, End-Stage Renal Disease (ESRD), or those on dialysis.

Population/Condition Eligibility Status (Regulatory Wording)
Adults (18+ years) Approved for all indications
Pediatric Use Approved for Type 2 Diabetes only (ge 10 years); Use not established for other indications in those < 18
Renal Function Not recommended for glycemic control if eGFR is < 45 mL/min/1.73 m^2
Pregnancy Not recommended during the second and third trimesters
Lactation/Breastfeeding Not recommended; advise to discontinue nursing or the drug
Severe Hepatic Impairment Not recommended

The medicine is not recommended for the treatment of patients with Type 1 Diabetes Mellitus or in those with severe hepatic impairment. Eligibility for heart failure or chronic kidney disease treatment allows use in patients with an eGFR as low as 25 mL/min/1.73 m^2 but is not recommended for initiation below this threshold.

What should I know about interactions with other medicines?

Interaction Scope

Category Details (Strictly from Regulatory Labels)
Medicinal product categories with documented interactions Insulin and Insulin Secretagogues, Diuretics (Loop and Thiazide), UGT1A9 enzyme inducers and inhibitors, and Lithium.
Specific interacting medicines (if explicitly listed) Rifampicin (UGT1A9 inducer), Mefenamic Acid (UGT1A9 inhibitor), Lithium.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Interaction: Additive effect on glycemic control (risk of hypoglycemia) and combined effect on fluid balance (risk of volume depletion/hypotension). Pharmacokinetic Interaction: Changes in dapagliflozin systemic exposure mediated by UGT1A9 enzyme activity.
Timing-based interaction rules (if applicable) Temporary interruption required for at least 3 days, if possible, before major surgery or procedures associated with prolonged fasting [FDA Labeling].
Population-specific interaction notes (if applicable) Elderly patients and those with impaired renal function have a higher incidence of adverse reactions related to hypotension when co-administered with diuretics. Severe hepatic impairment results in increased dapagliflozin exposure.
Interaction-related restrictions None listed as a formal drug-drug contraindication due to interaction risk.

Interaction Classifications (High-Level)

Classification Details (As Defined in Official Regulatory Documents)
Interaction severity classification (as defined in official documents) High Risk of Hypoglycemia (with insulin/secretagogues); High Risk of Volume Depletion/Hypotension (with diuretics); Exposure Modification (with UGT1A9 modulators).
Regulatory basis (EMA / FDA / etc.) Interaction statements are based on findings documented in the FDA Prescribing Information and the EMA European Public Assessment Report (EPAR).
Interaction-context constraints (as defined in official documents) Co-administration with insulin or secretagogues requires considering a lower dose of the co-administered agent.

Resulting Interaction Structure

The official interaction profile is defined by two primary concerns documented in regulatory sources: pharmacodynamic risks associated with volume depletion and hypoglycemia when co-administered with diuretics or insulin-related agents, and pharmacokinetic alterations driven by the UGT1A9 metabolic pathway. The regulatory documents confirm that the drug is not a significant modulator of the common CYP enzymes or major drug transporters, simplifying the overall interaction assessment to these specific PD and UGT1A9-mediated PK patterns.

Mechanism of Action

Farxiga (dapagliflozin) exerts its influence through a distinct, insulin-independent mechanism centered in the renal system. The drug functions as a competitive inhibitor of the Sodium-Glucose Co-transporter 2 (SGLT2), a protein located in the proximal renal tubules . This molecular action blocks the reabsorption of filtered glucose and associated sodium, initiating their excretion via urine. The resultant urinary loss of glucose (glucuresis) and sodium (natriuresis) leads to a reduction in circulating plasma glucose concentration.

The natriuresis and associated osmotic diuresis induce a mild reduction in circulating plasma volume. This volume decrease reduces the mechanical strain on the heart by lowering both preload and afterload, which results in altered cardiac mechanics. Furthermore, the increased sodium delivery to the distal tubule activates the tubuloglomerular feedback (TGF) mechanism. This feedback loop constricts the afferent arteriole, resulting in the reduction of pressure within the kidney's filtering units (glomeruli), completing the mechanistic cascade.

Dosage and Administration Information

The use of Farxiga (dapagliflozin) is strictly guided by the dosage and administration instructions outlined in official documents.

Administration Scope

Farxiga is formulated as an oral tablet and must be taken by mouth once daily. The tablet should be swallowed whole with a drink of water and should not be chewed, crushed, or split. Dosing may be done with or without food, but taking the medicine at approximately the same time each day is recommended to maintain consistency.

Official Dosing Rules

The approved dosage strengths for Farxiga are 5 mg and 10 mg tablets. The recommended dose is dependent on the specific indication, but is commonly 10 mg orally once daily for many uses in adults.

To improve blood sugar control in adults and children aged 10 and older with type 2 diabetes, the usual starting dose is 5 mg once daily. If further control is needed and the 5 mg dose is tolerated, it may be increased to the maximum recommended daily dose of 10 mg.

Important Procedural Instructions

Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must never take two doses at the same time to compensate for a missed dose.

Fluid Management: Patients are instructed to maintain adequate fluid intake during treatment, as the medicine can cause volume depletion.

Pre-Procedure Interruption: For patients undergoing major surgery or clinical situations associated with prolonged fasting (e.g., acute severe illness), the medicine must be temporarily withheld (stopped), if possible, for a defined period, generally at least three days, prior to the procedure.

Recent Clinical Evidence

Farxiga: Recent Clinical Evidence

Recent clinical research has focused on the effects of dapagliflozin (Farxiga) beyond its original use for managing blood glucose in Type 2 Diabetes Mellitus (T2DM). Large-scale randomized controlled trials (RCTs) have generated substantial evidence regarding its use in chronic heart failure and chronic kidney disease.

Cardiovascular Outcomes (Heart Failure)

Studies like the DAPA-HF and DELIVER trials have evaluated dapagliflozin's effects on heart failure (HF) in adults, regardless of whether they have T2DM. The DAPA-HF trial demonstrated a reduction in the risk of worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF). The DELIVER trial further extended these findings, suggesting benefits in patients with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Renal Outcomes (Chronic Kidney Disease)

The DAPA-CKD trial evaluated dapagliflozin's effect on chronic kidney disease (CKD) in patients with and without T2DM. This trial assessed a composite endpoint of sustained decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease (ESKD), or death from cardiovascular or renal causes. The findings suggested a reduction in the risk of these cardiorenal outcomes compared to placebo when dapagliflozin was added to standard care. The effects were observed consistently across different causes of CKD.

Tolerability Profile

Across these major trials, the tolerability profile of dapagliflozin was generally consistent with previously established safety data. Common adverse events reported included genital mycotic infections and urinary tract infections, consistent with the mechanism of action.

Frequently Asked Questions (FAQ)

Common questions about Farxiga (FAQ)

Q: Is Farxiga a type of insulin?

A: No, Farxiga (dapagliflozin) is not an insulin product. It belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors. These medications work independently of insulin by helping the kidneys remove glucose from the body through the urine.

Q: What is the main use of Farxiga?

A: Farxiga is approved for several uses, including improving blood sugar control in adults with Type 2 diabetes. It is also approved for reducing the risk of cardiovascular death and hospitalization for heart failure in certain adults with heart failure, and for reducing the risk of kidney function decline in certain adults with chronic kidney disease.

Q: If I miss a dose, what should I do?

A: If a dose is missed, it should generally be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the person should return to their regular schedule. It is important to not take two doses at the same time. Specific directions for missed doses should always come from a healthcare provider.

Q: How long does it take for Farxiga to start working?

A: Farxiga begins working to increase the amount of glucose removed in the urine relatively quickly after starting treatment. However, the full effects on A1C levels (a measure of long-term blood sugar control) or its protective effects on the heart and kidneys are observed over weeks or months of consistent use.

Q: Will Farxiga help me lose weight?

A: Weight loss is not the primary approved use of Farxiga. However, because it causes the body to excrete excess glucose (sugar) through the urine, some patients may experience modest weight loss. This effect can vary among individuals.

How should Farxiga be stored and disposed of?

Storage and Disposal Instructions for Farxiga

Farxiga (dapagliflozin) tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The medication must be protected from excess heat and moisture and must not be frozen.

Storage Requirements

Condition Requirement
Temperature 20°C to 25°C (68°F to 77°F)
Protection Keep away from heat and moisture
Container Keep in original container, tightly closed
Safety Store out of the reach of children

Disposal

Unused or expired tablets should be disposed of using a drug take-back program whenever possible. If a program is unavailable, the tablets should be mixed with an undesirable substance (such as dirt) and placed in a sealed container before discarding in the household trash. Do not flush Farxiga down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Farxiga found in:

A-Z Index: